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ABSTRACT
Introduction: Chronic inflammation of longstanding duration has been linked to the development of carcinoma in several
organ systems. It is controversial whether there is any relationship of inflammatory atrophy to prostate cancer. It has been
suggested that the proliferative epithelium in inflammatory atrophy may progress to high-grade prostatic intraepithelial
neoplasia and/or adenocarcinoma. The objective of our study is to compare on needle prostate biopsies of patients
showing cancer the topographical relation of inflammatory atrophy and atrophy with no inflammation to adenocarcinoma.
Materials and Methods: The frequency and extent of the lesions were studied on 172 needle biopsies of patients with
prostate cancer. In cores showing both lesions, the foci of atrophy were counted. Clinicopathological features were com-
pared according to presence or absence of inflammation.
Results: Considering only cores showing adenocarcinoma, atrophy was seen in 116/172 (67.44%) biopsies; 70/116 (60.34%)
biopsies showed atrophy and no inflammation and 46/116 (39.66%) biopsies showed inflammatory atrophy. From a total of
481 cores in 72 biopsies with inflammatory atrophy 184/481 (38.25%) cores showed no atrophy; 166/481 (34.51%) cores
showed atrophy and no inflammation; 111/481 (23.08%) cores showed both lesions; and 20/481 (4.16%) showed only
inflammatory atrophy. There was no statistically significant difference for the clinicopathological features studied.
Conclusion: The result of our study seems not to favor the model of prostatic carcinogenesis in which there is a topographi-
cal relation of inflammatory atrophy to adenocarcinoma.
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INTRODUCTION
Chronic inflammation of longstanding dura-
tion has been linked to the development of carcinoma
in several organ systems (1-3). In the prostate, it is
controversial whether there is any relationship of at-
rophy with inflammation (or inflammatory atrophy) to
prostate cancer (4-10). De Marzo et al. (5) propose
that there is a topographical relation with morphologi-
cal transitions within the same acinar/duct unit, be-
tween high-grade prostatic intraepithelial neoplasia
(HGPIN) and inflammatory atrophy which occur fre-
quently (7). This finding supports a model whereby
the proliferative epithelium in inflammatory atrophy
may progress to HGPIN and subsequently to adeno-
carcinoma. The aim of this study is to compare in
cores of needle biopsies of patients showing prostate
cancer the topographic relation of inflammatory atro-
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phy and atrophy with no inflammation to adenocarci-
noma.
MATERIALS AND METHODS
The material of this retrospective study was
obtained from 172 consecutive men with cancer on
needle prostate biopsies and subsequently submitted
to radical retropubic prostatectomy.
Both partial and complete prostatic atrophy
were considered. Partial prostatic atrophy was diag-
nosed according to criteria described by Oppenheimer
et al. (11) and complete atrophy by criteria described
by Billis (4). Three histological subtypes were identi-
fied: simple atrophy, hyperplastic atrophy (or
postatrophic hyperplasia) (Figure-1), and sclerotic at-
rophy. Elastosis of the stroma was a useful micro-
scopic feature for the identification of prostatic atro-
phy of any subtype (12).
Inflammatory atrophy (prostatic atrophy with
inflammation) - Both inactive and active inflamma-
tion were considered. Inflammatory infiltrate with lym-
phocytes, plasmacytes or macrophages was consid-
ered inactive. The infiltrate was considered active
whenever neutrophils were seen in the stroma. All
grades of inflammation were considered according to
a modified consensus development of a histopatho-
logical classification system for chronic prostatic in-
flammation (13): mild (scattered individual inflamma-
tory cells), moderate (clusters of inflammatory cells)
and severe (confluent sheets of inflammatory cells)
in areas of prostatic atrophy of any kind: simple, hy-
perplastic (Figure-2) or sclerotic.
According to the pathologic findings, patients
were stratified into group A (biopsies with atrophy and
no inflammation), and group B (biopsies with inflam-
matory atrophy).
The frequency of atrophy was evaluated con-
sidering all cores of the biopsy as well as only the
cores showing adenocarcinoma. Extent of inflamma-
tory atrophy and atrophy with no inflammation was
evaluated according to the number of cores showing
the lesion. In group B, we counted the cores showing
only inflammatory atrophy, cores showing atrophy and
no inflammation, and cores showing both lesions. In
cores showing both inflammatory atrophy and atro-
phy with no inflammation, the foci of each lesion were
counted using an image analyzer (ImageLab-2000).
The clinicopathological features included age
of the patients, preoperative PSA, and biopsy Gleason
score.
The data were analyzed using the Mann-
Whitney test for comparison of continuous variables
Figure 1 – Atrophy with no inflammation, hyperplastic subtype
(HE, X100).
Figure 2 – Inflammatory atrophy, hyperplastic subtype (HE,
X200).
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with P < 0.05 being considered statistically significant.
All statistical analyses were performed using Statistica
5.5 (StatSoft, Inc., Tulsa, OK, USA).
RESULTS
A total of 1,088 cores (mean, median and
range 6.32, 6 and 1-13, respectively) were obtained
from 172 needle biopsies of patients with prostate
cancer. Considering all cores of the biopsy, atrophy
was seen in 144/172 (83.72%) biopsies; 72/144 (50%)
biopsies showed atrophy with no inflammation and 72/
144 (50%) biopsies showed inflammatory atrophy. In
57/72 (79.16%) biopsies with inflammatory atrophy
inflammation was inactive, and in 15/72 (20.83%) bi-
opsies inflammation was active.
Considering only cores showing adenocarci-
noma, atrophy was seen in 116/172 (67.44%) biop-
sies; 70/116 (60.34%) biopsies showed atrophy with
no inflammation and 46/116 (39.66%) biopsies showed
inflammatory atrophy (Table-1).
There was a total of 481 cores in the 72 biop-
sies with inflammatory atrophy; 184/481 (38.25%)
cores showed no atrophy; 166/481 (34.51%) cores
showed atrophy and no inflammation; 111/481
(23.08%) cores showed both lesions; and, 20/481
(4.16%) cores showed only inflammatory atrophy
(Table-2). In the cores showing both lesions, inflam-
matory atrophy was seen in 193/398 (48.49%) foci,
and atrophy with no inflammation was seen in 205/
398 (51.51%) foci.
Table-3 shows the clinicopathologic features
by groups A and B according to age, preoperative PSA
and biopsy Gleason score. There was no statistically
significant difference between patients showing atro-
phy and no inflammation (group A) and patients show-
ing inflammatory atrophy (group B).
COMMENTS
Prostatic atrophy is one of the most frequent
mimics of prostatic adenocarcinoma (14). It occurs
most frequently in the posterior lobe or peripheral zone
(15) and gained importance with the increasing use of
needle biopsies for the detection of prostatic carci-
noma (16). The frequency of the lesion in autopsies is
85% and increases with age (4). The etiopathogen-
esis of prostatic atrophy is unknown. Compression due
to hyperplastic nodules, inflammation, hormones, nu-
tritional deficiency, systemic or local ischemia, are all
factors that may play a role in the pathogenesis of
atrophy (4,14,15,17,18). The histologic subtypes of
Table 1 – Frequency of atrophy in 172 biopsies considering only cores showing adenocarcinoma.
Findings       N   %
Biopsies with atrophy (groups A + B) 116/172 67.44
Biopsies with atrophy and no inflammation (group A) 070/116 60.34
Biopsies with inflammatory atrophy (group B) 046/116 39.66
Table 2 – Findings in 481 cores from 72 biopsies showing inflammatory atrophy.
Findings     N %
Cores without atrophy 184/481 38.25
Cores showing atrophy and no inflammation 166/481 34.51
Cores showing both lesions 111/481 23.08
Cores showing only inflammatory atrophy 020/481 04.16
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Table 3 – Clinicopathologic features of 172 patients with prostate cancer in the biopsy by groups A (with atrophy and
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SD = standard deviation, § = Mann-Whitney test.
prostatic atrophy do not represent distinct entities but
a morphologic continuum of acinar atrophy. Subtyping
atrophy is useful not only for its recognition, and for
distinguishing it from prostate cancer (4,16).
Chronic inflammation of longstanding dura-
tion has been linked to the development of carcinoma
in several organ systems (1-3). In the prostate, it is
controversial whether there is any relationship of in-
flammatory atrophy to prostate cancer (4-10). The
term “proliferative inflammatory atrophy” was pro-
posed by De Marzo et al. (5) to designate discrete
foci of proliferative glandular epithelium with the mor-
phological appearance of simple atrophy or
postatrophic hyperplasia occurring in association with
inflammation. According to these authors the morphol-
ogy of proliferative inflammatory atrophy is consis-
tent with McNeal’s description of postinflammatory
atrophy (19), with that of chronic prostatitis described
by Bennett et al. (20), and with the lesion referred to
previously as “lymphocytic prostatitis” by Blumenfeld
et al. (21). De Marzo et al. (5) and Putzi and De Marzo
(7) suggest that proliferative atrophy may indeed give
rise to carcinoma directly or that proliferative atrophy
may lead to carcinoma indirectly via development into
HGPIN. This hypothesis by the authors is based on
three separate findings providing supportive evidence:
1) A topographical relation with morphologic merging
between proliferative inflammatory atrophy and
HGPIN in 34% of the inflammatory atrophy lesions;
2) The phenotype of many of the cells in inflamma-
tory atrophy is most consistent with that of an imma-
ture secretory-type cell, similar to that for the cells of
HGPIN; and 3) proliferative inflammatory atrophy,
HGPIN, and carcinoma all occur with high prevalence
in the peripheral zone and low prevalence in the cen-
tral zone of the human prostate.
Favoring a link of inflammation to prostate
adenocarcinoma, Cohen et al. (22) found a positive
association between Propionibacterium acnes and
prostatic inflammation, which may be implicated in
the development of prostate cancer. However, the
authors comment that it is possible that prostatic in-
flammation may also be caused by other microorgan-
isms which could not be identified by the study, for
example obligate anerobes or species which are diffi-
cult to culture under laboratory conditions. They also
comment on a second important limitation of the study
related to the lack of appropriate negative controls
such as prostate tissue from patients without inflam-
mation, atrophy and cancer.
Other studies are at odds with the findings of
De Marzo et al. (5) and Putzi and De Marzo (7). In
100 consecutively autopsied men more than 40 years
of age, Billis (4) studied the etiopathogenesis of atro-
phy and its possible potential as a precancerous le-
sion. There was no statistically significant relation of
atrophy to histologic (incidental) carcinoma or HGPIN.
The author concluded that prostatic atrophy probably
is not a premalignant lesion. In this autopsy study,
prevalence of atrophy increased with age and chronic
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ischemia caused by local intense arteriosclerosis
seemed to be a potential factor for its pathogenesis.
In a subsequent study, Billis and Magna (9) stratified
the 100 prostates into group A (atrophy without in-
flammation) and group B (inflammatory atrophy). The
groups were correlated to age, race, histologic (inci-
dental) carcinoma, HGPIN, and extent of both these
latter lesions. There was no statistically significant
difference between groups A and B for all the vari-
ables studied. Neither a topographical relation nor a
morphologic transition was seen between prostatic
atrophy and histologic carcinoma or HGPIN. The
authors concluded that inflammatory atrophy does not
appear to be associated with cancer or HGPIN.
Anton et al. (6) studying 272 radical prostate-
ctomies and 44 cystoprostatectomies concluded that
postatrophic hyperplasia is a relatively common le-
sion present in about one-third of prostates, either with
or without prostate carcinoma. The authors found no
association between the presence of postatrophic hy-
perplasia and the likelihood of cancer and no topo-
graphic association between postatrophic hyperplasia
and prostate carcinoma foci.
Bakshi et al. (8) studied 79 consecutive pros-
tate biopsies: 54% of initial biopsies were benign, 42%
of the cases showed cancer, and 4% HGPIN or aty-
pia. Postatrophic hyperplasia was seen in 17% of be-
nign initial biopsies with available follow-up. Of these,
75% had associated inflammation. There was no sig-
nificant difference in the subsequent diagnosis of pros-
tate cancer for groups with postatrophic hyperplasia,
partial atrophy, atrophy, or no specific abnormality. The
authors concluded that the subcategories of atrophy
do not appear to be associated with a significant in-
crease in the risk of diagnosis of prostate cancer sub-
sequently.
Postma et al. (10) evaluated whether the in-
cidence of atrophy reported on sextant biopsies is as-
sociated with subsequent prostate cancer detection.
The authors concluded that atrophy is a very com-
mon lesion in prostate biopsy cores (94%). Atrophy in
an asymptomatic population undergoing screening was
not associated with a greater prostate cancer or
HGPIN incidence during subsequent screening rounds.
In the present study, from a total of 172 needle
biopsies of men with prostate cancer, 144/172 showed
atrophy; 72/144 (50%) biopsies showed atrophy and
no inflammation and 72/144 (50%) biopsies showed
inflammatory atrophy. However, considering only
cores with cancer, atrophy was seen in 116/172
(67.44%) biopsies; 70/116 (60.34%) biopsies showed
atrophy and no inflammation and 46/116 (39.66%) bi-
opsies showed inflammatory atrophy. This finding
seems to contradict the topographical model by De
Marzo et al. (5) whereby inflammatory atrophy may
progress directly to adenocarcinoma or indirectly via
development to HGPIN. In cores with adenocarci-
noma it would be expected a higher frequency of in-
flammatory atrophy. Another relevant finding in our
study was the evaluation of the extension of inflam-
matory atrophy in the 481 cores of the 72 biopsies
showing this lesion. In only 20/481 (4.16%) cores in-
flammatory atrophy was the only lesion present. Most
frequently cores showed either atrophy with no in-
flammation (166/481, 34.51%) or both lesions (111/
481, 23.08%). A criticism to our findings is that a thin
prostate needle biopsy may not represent a real topo-
graphic relation between lesions if compared to find-
ings in large specimens such as radical prostatectomy
or autopsy prostates. In the study on autopsies with
step-sectioning of the prostate, a topographic relation
of inflammatory atrophy and HGPIN and/or histologic
adenocarcinoma was also not found (9).
There was no statistically significant differ-
ence for age (P = 0.7487), preoperative PSA (P =
0.7950), and Gleason score in the biopsy (P = 0.5143)
between patients with atrophy and no inflammation
and patients with inflammatory atrophy probably indi-
cating no difference in temporal onset and aggres-
siveness of the tumor in this two groups.
CONCLUSION
The result of our study seems not to favor
the model of prostatic carcinogenesis in which there
is a topographical relation of inflammatory atrophy to
adenocarcinoma. In cores with adenocarcinoma, at-
rophy with no inflammation was more frequently seen
than inflammatory atrophy, and in biopsies with in-
flammatory atrophy, only 4.16% of the cores showed
this lesion as the only finding.
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EDITORIAL COMMENT
High-grade prostatic intraepithelial neoplasia
(HGPIN) is the most likely precursor of prostatic ad-
enocarcinoma, according to virtually all available evi-
dence. There are other possible findings in the prostate
that may be premalignant (Low-grade PIN, inflamma-
tory atrophy, malignancy-associated foci, and atypical
adenomatous hyperplasia), but the data for them are
much less convincing than that for HGPIN (1).
The paper by Athanase Billis and collabora-
tors entitled “Inflammatory Atrophy on Prostate
Needle Biopsies: Is There Topographic Relationship
to Cancer?” deals with the interesting topic of
preneoplastic lesions and conditions of the prostate, in
particular with proliferative inflammatory atrophy (2).
The objective of their study was to compare on needle
prostate biopsies of patients showing cancer the to-
pographical relation of inflammatory atrophy and at-
rophy with no inflammation to adenocarcinoma. The
result of their study did not favor the model of pros-
tatic carcinogenesis in which there is a topographical
relation of inflammatory atrophy to adenocarcinoma.
Dr Billis’ study does not exclude that inflammatory
atrophy could be an early step in the development of
prostate cancer and one of the possible preneoplastic
conditions and lesions that precede the appearance of
cancer.
Low-grade PIN (LGPIN) - Earlier morpho-
metric and immunohistochemical studies showed that
LGPIN has features that are intermediate between
normal tissue and HGPIN (1). Little information on
LGPIN has been accumulated in recent times. This is
probably due to the fact, while HGPIN in needle bi-
opsy tissue is a risk factor for the subsequent detec-
tion of carcinoma, LGPIN is not. Currently, LGPIN is
not documented in pathology reports due a relatively
low risk of cancer following re-biopsy.
In Bostwick’s progression model of PIN to
carcinoma, the transition between normal, low-grade
PIN, high-grade PIN, and then carcinoma is continu-
ous (3). Few epidemiologic, morphologic, or molecu-
lar genetic studies have examined the relation between
low and high-grade PIN development. In part, this
relates to the difficulty in distinguishing low-grade PIN
from normal tissue on the one hand and high-grade
PIN on the other. Nevertheless, Putzi and De Marzo
(4) found that lesions that could be considered low-
grade PIN often coexisted with high-grade PIN, sug-
gesting either that high-grade PIN is derived from low-
grade PIN or that high and low grade PIN arise con-
comitantly.
Focal Prostate Atrophy as a Morphological
Manifestation of a “Field Effect” and a Potential Pros-
tate Cancer Precursor - Pathologists have long rec-
ognized focal areas of epithelial atrophy in the pros-
tate that appear more commonly in the peripheral zone
of the prostate. These lesions may be associated with
chronic inflammation, and less commonly with acute
inflammation (5). The term proliferative inflammatory
atrophy (PIA) has been proposed (5).
Many of the atrophic cells are not quiescent
and possess a phenotype that is intermediate between
basal and luminal cells. Intermediate epithelial cells
have been postulated to be the targets of neoplastic
transformation in the prostate (6). Additionally, PIA
cells show elevated levels of GSTP1, glutathione S
transferase alpha (GSTA1) and COX-2 in many cells,
suggesting that these cells are responding to increased
oxidant/nitrosative/electrophilic stress. Many of the
molecular and genetic changes seen in HGPIN and
cancer have also been documented in PIA (7).
In morphological studies, it has been observed
frequent merging of areas of focal atrophy directly
with high grade PIN (7). It has been observed these
atrophic lesions near early carcinoma lesions, at times
with direct merging between atrophic epithelium in
PIA and adenocarcinoma (7). Some of such changes
could be called atrophic HGPIN.
Malignancy-associated changes (Putative
preneoplastic markers with minimal or no morphologi-
cal changes) - Malignancy-associated changes refer
to molecular abnormalities in the epithelial cells that
are not usually distinguishable by routine light micro-
scopic examination.
Scant data are available in the prostate. Nor-
mal-looking epithelium in prostates with adenocarci-
noma may show some molecular abnormalities in
GSTP- I and telomerase that are similar to those in
cancer (2). These observations are related to the so-
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called “enzyme-altered foci” as putative preneoplastic
markers (8,9). According to Dr TG Pretlow and co-
workers, the most abundant of these lesions with
molecular alterations show minimal or no morphologi-
cal changes (8). Changes occur also in the stroma.
Montironi et al (10) have shown that the degree of
vascularization in normal-looking prostate tissue from
total prostatectomies performed because of a preop-
erative diagnosis of PCa is close to that of LGPIN.
The transition from normal-looking epithelium
to prostate cancer without an intermediate morpho-
logical stage identifiable as HGPIN was considered
possible (8). This raises the question of the existence
of PIN without morphological changes as a precursor
of some well-differentiated adenocarcinomas of the
transition zone.
Atypical adenomatous hyperplasia – AAH
(Adenosis) - Is characterized by a circumscribed pro-
liferation of closely packed small glands that tends to
merge with the surrounding, histologically benign
glands (11). AAH has been considered a premalig-
nant lesion of the transition zone. A direct transition
from AAH to cancer, as it has been observed be-
tween HGPIN and cancer, has not been documented.
The link between cancer and AAH is probably an
epiphenomenon and that the data are insufficient to
conclude that AAH is a premalignant lesion.
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EDITORIAL COMMENT
A hypothesis for prostate carcinogenesis pro-
poses that injury to the prostate from a variety of
causes leads to chronic inflammation and prolifera-
tive inflammatory atrophy (PIA) which may be a
risk factor for prostate cancer. Prostatic glandular
atrophy can be diffuse or focal with diffuse atrophy
resulting from androgen deprivation. PIA is a type
of focal atrophy that occurs in the absence of an-
drogen deprivation and occurs in small or large foci,
most commonly in the peripheral zone. Recognized
morphological types of PIA include simple atrophy
and postatrophic hyperplasia in which chronic inflam-
mation as well as increased proliferative activity has
been demonstrated. It is unknown whether the other
types of focal atrophy, including simple atrophy with
cyst formation and partial atrophy have increased
cellular proliferation. Therefore, these lesions are
currently not considered PIA. A variety of other
carcinomas including those in the liver, stomach, large
bowel and urinary bladder appear to be related to
long-standing chronic inflammation and proliferation.
Prostate cancer and its precursor, high-grade pros-
tatic intraepithelial neoplasia (HGPIN) have has been
linked with PIA lesions through topographical and
morphological associations. De Marzo et al. (1) have
shown frequent morphological transitions between
HGPIN and PIA suggesting that PIA may be a high-
risk lesion for prostate cancer through HGPIN. Al-
though topographical and morphological associations
alone are not proofs of a cancer-causing role for
PIA lesions, these support a model of prostatic car-
cinogenesis in proliferative epithelium in chronic in-
flammation. The authors studied needle core biop-
sies of patients with prostate cancer and did not show
a topographical relationship of inflammatory atrophy
to adenocarcinoma. Other studies have shown simi-
lar results with inflammatory atrophy found to be a
very common lesion. These findings, while not sup-
porting this model of prostate carcinogenesis, do not
rule out this association and ultimately experimental
animal studies, epidemiological studies and molecu-
lar pathological approaches are needed to clarify this
hypothesis.
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